Skip to main content
Top
Published in: Netherlands Heart Journal 2/2024

Open Access 20-10-2023 | Digoxin | Point of View

Digoxin-specific antibodies: a novel dosing strategy

Authors: Marieke A. Dijkman, Femke M. J. Gresnigt, Dylan W. de Lange

Published in: Netherlands Heart Journal | Issue 2/2024

Login to get access

Abstract

Digoxin-specific antibodies (digoxin-Fabs) are of value in the treatment of a strongly suspected or a known, potentially life-threatening digoxin toxicity. These antibodies are not registered for use in Europe; therefore Dutch hospital pharmacies are not allowed to keep them in stock. In the Netherlands, digoxin-Fabs are stored in a national calamity stock of emergency medicines at the National Institute for Public Health and the Environment. In the case of a medical emergency, digoxin-Fabs are available after contact with the Dutch Poisons Information Centre. Recent studies have shown that the dose of digoxin-Fabs required to effectively treat digoxin toxicity is lower than previously thought. In this article, we present the adjusted digoxin-Fab dosing strategy currently recommended by the Dutch Poisons Information Centre (www.​vergiftigingen.​info). This new dose titration strategy is safe and effective and has a cost-saving side-effect.
Literature
2.
go back to reference Smith TW, Haber E, Yeatman L, Butler VP Jr.. Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. N Engl J Med. 1976;294:797–800.CrossRefPubMed Smith TW, Haber E, Yeatman L, Butler VP Jr.. Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. N Engl J Med. 1976;294:797–800.CrossRefPubMed
3.
go back to reference Wei S, Niu MT, Dores GM. Adverse events associated with the use of digoxin immune Fab reported to the US Food and Drug Administration Adverse event reporting system, 1986–2019. Drugs Real World Outcomes. 2021;8:253–62.CrossRefPubMedPubMedCentral Wei S, Niu MT, Dores GM. Adverse events associated with the use of digoxin immune Fab reported to the US Food and Drug Administration Adverse event reporting system, 1986–2019. Drugs Real World Outcomes. 2021;8:253–62.CrossRefPubMedPubMedCentral
4.
go back to reference Ujhelyi MR, Robert S. Pharmacokinetic aspects of digoxin-specific Fab therapy in the management of digitalis toxicity. Clin Pharmacokinet. 1995;28:483–93.CrossRefPubMed Ujhelyi MR, Robert S. Pharmacokinetic aspects of digoxin-specific Fab therapy in the management of digitalis toxicity. Clin Pharmacokinet. 1995;28:483–93.CrossRefPubMed
6.
go back to reference Smith SW, Howland MA. Digoxin-specific antibody fragments. In: Nelson LS, Howland MA, Lewin NA, Smith SW, Goldfrank LR, Hoffman RS, editors. Goldfrank’s Toxicologic Emergencies. Vol. 11. 2019. pp. 977–84. Smith SW, Howland MA. Digoxin-specific antibody fragments. In: Nelson LS, Howland MA, Lewin NA, Smith SW, Goldfrank LR, Hoffman RS, editors. Goldfrank’s Toxicologic Emergencies. Vol. 11. 2019. pp. 977–84.
7.
go back to reference Chan BSH, Buckley NA. Digoxin-specific antibody fragments in the treatment of digoxin toxicity. Clin Toxicol. 2014;52:824–36.CrossRef Chan BSH, Buckley NA. Digoxin-specific antibody fragments in the treatment of digoxin toxicity. Clin Toxicol. 2014;52:824–36.CrossRef
8.
go back to reference Bateman DN. Digoxin-specific antibody fragments: how much and when? Toxicol Rev. 2004;23:135–43.CrossRefPubMed Bateman DN. Digoxin-specific antibody fragments: how much and when? Toxicol Rev. 2004;23:135–43.CrossRefPubMed
9.
go back to reference Chan BS, Isbister GK, Chiew A, Isoardi K, Buckley NA. Clinical experience with titrating doses of digoxin antibodies in acute digoxin poisoning. (ATOM-6). Clin Toxicol. 2022;60:433–9.CrossRef Chan BS, Isbister GK, Chiew A, Isoardi K, Buckley NA. Clinical experience with titrating doses of digoxin antibodies in acute digoxin poisoning. (ATOM-6). Clin Toxicol. 2022;60:433–9.CrossRef
10.
go back to reference Scherrmann JM. Antibody treatment of toxin poisoning—recent advances. J Toxicol Clin Toxicol. 1994;32:363–75.CrossRefPubMed Scherrmann JM. Antibody treatment of toxin poisoning—recent advances. J Toxicol Clin Toxicol. 1994;32:363–75.CrossRefPubMed
11.
go back to reference Flanagan RJ, Jones AL. Fab antibody fragments: some applications in clinical toxicology. Drug Safety. 2004;27:1115–33.CrossRefPubMed Flanagan RJ, Jones AL. Fab antibody fragments: some applications in clinical toxicology. Drug Safety. 2004;27:1115–33.CrossRefPubMed
12.
go back to reference Mowry JB, Burdmann EA, Anseeuw K, et al. Extracorporeal treatment for digoxin poisoning: systematic review and recommendations from the EXTRIP Workgroup. Clin Toxicol. 2016;54:103–14.CrossRef Mowry JB, Burdmann EA, Anseeuw K, et al. Extracorporeal treatment for digoxin poisoning: systematic review and recommendations from the EXTRIP Workgroup. Clin Toxicol. 2016;54:103–14.CrossRef
13.
go back to reference Chan BS, Isbister GK, Page CB, et al. Clinical outcomes from early use of digoxin-specific antibodies versus observation in chronic digoxin poisoning (ATOM-4). Clin Toxicol. 2019;57:638–43.CrossRef Chan BS, Isbister GK, Page CB, et al. Clinical outcomes from early use of digoxin-specific antibodies versus observation in chronic digoxin poisoning (ATOM-4). Clin Toxicol. 2019;57:638–43.CrossRef
14.
go back to reference Chan BS, Isbister GK, O’Leary M, Chiew A, Buckley NA. Efficacy and effectiveness of anti-digoxin antibodies in chronic digoxin poisonings from the DORA study (ATOM-1). Clin Toxicol. 2016;54:488–94.CrossRef Chan BS, Isbister GK, O’Leary M, Chiew A, Buckley NA. Efficacy and effectiveness of anti-digoxin antibodies in chronic digoxin poisonings from the DORA study (ATOM-1). Clin Toxicol. 2016;54:488–94.CrossRef
15.
go back to reference Nordt SP, Clark RF, Machado C, Lee Cantrell F. Assessment of digoxin-specific Fab fragment dosages in digoxin poisoning. Am J Ther. 2016;23:e63–e7.CrossRefPubMed Nordt SP, Clark RF, Machado C, Lee Cantrell F. Assessment of digoxin-specific Fab fragment dosages in digoxin poisoning. Am J Ther. 2016;23:e63–e7.CrossRefPubMed
Metadata
Title
Digoxin-specific antibodies: a novel dosing strategy
Authors
Marieke A. Dijkman
Femke M. J. Gresnigt
Dylan W. de Lange
Publication date
20-10-2023
Publisher
Bohn Stafleu van Loghum
Published in
Netherlands Heart Journal / Issue 2/2024
Print ISSN: 1568-5888
Electronic ISSN: 1876-6250
DOI
https://doi.org/10.1007/s12471-023-01814-y

Other articles of this Issue 2/2024

Netherlands Heart Journal 2/2024 Go to the issue